The higher median CRP/Alb ratio observed in advanced-stage patients compared to the early-stage patients (10.28 vs. 0.98, p = 0.005) supports an earlier study associating CRP/Alb with a more aggressive disease phenotype in ovarian cancer [112]. The gene discussed is CRP; the disease is ovarian cancer.